{"id":191828,"date":"2017-05-09T14:58:51","date_gmt":"2017-05-09T18:58:51","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/global-psoriasis-therapeutics-pipeline-review-h1-2017-research-and-markets-business-wire-press-release\/"},"modified":"2017-05-09T14:58:51","modified_gmt":"2017-05-09T18:58:51","slug":"global-psoriasis-therapeutics-pipeline-review-h1-2017-research-and-markets-business-wire-press-release","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/global-psoriasis-therapeutics-pipeline-review-h1-2017-research-and-markets-business-wire-press-release\/","title":{"rendered":"Global Psoriasis Therapeutics Pipeline Review, H1 2017 &#8211; Research and Markets &#8211; Business Wire (press release)"},"content":{"rendered":"<p><p>    DUBLIN--(BUSINESS    WIRE)--Research and Markets    has announced the addition of the \"Psoriasis - Pipeline Review, H1 2017\"    report to their offering.  <\/p>\n<p>    Psoriasis is a chronic skin condition caused by an overactive    immune system. Symptoms of the disease include shedding of    cells, flared up skin, itchiness, and burning sensation,    swollen and stiff joints. Predisposing factors include    heredity, side effects of certain medicines, stress, infections    and environmental conditions. The condition may be controlled    by topical or systemic medications and phototherapy.  <\/p>\n<p>    Pharmaceutical and Healthcare latest pipeline guide Psoriasis -    Pipeline Review, H1 2017, provides comprehensive information on    the therapeutics under development for Psoriasis (Immunology),    complete with analysis by stage of development, drug target,    mechanism of action (MoA), route of administration (RoA) and    molecule type. The guide covers the descriptive pharmacological    action of the therapeutics, its complete research and    development history and latest news and press releases.  <\/p>\n<p>    The Psoriasis (Immunology) pipeline guide also reviews of key    players involved in therapeutic development for Psoriasis and    features dormant and discontinued projects. The guide covers    therapeutics under Development by Companies \/Universities    \/Institutes, the molecules developed by Companies in    Pre-Registration, Filing rejected\/Withdrawn, Phase III, Phase    II, Phase I, IND\/CTA Filed, Preclinical, Discovery and Unknown    stages are 14, 1, 21, 44, 42, 1, 103, 32 and 9 respectively.    Similarly, the Universities portfolio in Preclinical and    Discovery stages comprises 8 and 6 molecules, respectively.  <\/p>\n<p>    Psoriasis (Immunology) pipeline guide helps in identifying and    tracking emerging players in the market and their portfolios,    enhances decision making capabilities and helps to create    effective counter strategies to gain competitive advantage.  <\/p>\n<p>    Key Topics Covered:  <\/p>\n<p>    For more information about this report visit <a href=\"http:\/\/www.researchandmarkets.com\/research\/4kcrcl\/psoriasis\" rel=\"nofollow\">http:\/\/www.researchandmarkets.com\/research\/4kcrcl\/psoriasis<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>The rest is here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\/news\/home\/20170508006087\/en\/Global-Psoriasis-Therapeutics-Pipeline-Review-H1-2017\" title=\"Global Psoriasis Therapeutics Pipeline Review, H1 2017 - Research and Markets - Business Wire (press release)\">Global Psoriasis Therapeutics Pipeline Review, H1 2017 - Research and Markets - Business Wire (press release)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the \"Psoriasis - Pipeline Review, H1 2017\" report to their offering. Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/global-psoriasis-therapeutics-pipeline-review-h1-2017-research-and-markets-business-wire-press-release\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-191828","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/191828"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=191828"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/191828\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=191828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=191828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=191828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}